Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 13, 2023 16:05 ET | Source: DICE Therapeutics, Inc.

DICE Therapeutics to Host R&D Investor Event on Tuesday, June 20, 2023

SOUTH SAN FRANCISCO, Calif., June 13, 2023 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE) (DICE or the Company), a biopharmaceutical company leveraging its proprietary DELSCAPE...
May 11, 2023 16:05 ET | Source: DICE Therapeutics, Inc.

DICE Therapeutics Reports First Quarter 2023 Financial Results and Recent Highlights

First patient dosed in global Phase 2b clinical trial of lead oral IL-17 inhibitor, DC-806, in moderate-to-severe psoriasisTopline data from Phase 1 clinical trial of second oral IL-17 inhibitor,...
May 03, 2023 16:05 ET | Source: DICE Therapeutics, Inc.

DICE Therapeutics to Participate in the Bank of America Securities 2023 Healthcare Conference

SOUTH SAN FRANCISCO, Calif., May 03, 2023 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE) (DICE or the Company), a biopharmaceutical company leveraging its proprietary DELSCAPE technology...
March 23, 2023 16:05 ET | Source: DICE Therapeutics, Inc.

DICE Therapeutics to Participate in the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference

SOUTH SAN FRANCISCO, Calif., March 23, 2023 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE) (DICE or the Company), a biopharmaceutical company leveraging its proprietary DELSCAPE...
March 15, 2023 16:05 ET | Source: DICE Therapeutics, Inc.

DICE Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Highlights

IND application for DICE’s lead oral IL-17 antagonist, DC-806, cleared by FDA; global Phase 2b clinical trial in patients with moderate-to-severe psoriasis on track to initiate in 1H 2023First...
March 01, 2023 16:05 ET | Source: DICE Therapeutics, Inc.

DICE Therapeutics Announces Late-Breaking Presentation at the 2023 American Academy of Dermatology (AAD) Annual Meeting

SOUTH SAN FRANCISCO, Calif., March 01, 2023 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline...
February 08, 2023 16:05 ET | Source: DICE Therapeutics, Inc.

DICE Therapeutics to Participate at Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Feb. 08, 2023 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline...
January 04, 2023 16:05 ET | Source: DICE Therapeutics, Inc.

DICE Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline...
November 09, 2022 16:05 ET | Source: DICE Therapeutics, Inc.

DICE Therapeutics Reports Third Quarter 2022 Financial Results and Recent Highlights

Reported positive Phase 1 proof-of-concept data supporting the further development of lead oral IL-17 antagonist, DC-806, as potential best-in-class oral agent for psoriasisDemonstrated direct...
November 03, 2022 16:05 ET | Source: DICE Therapeutics, Inc.

DICE Therapeutics to Present at Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline...